Article
Cardiac & Cardiovascular Systems
Julia Karady, Thomas Mayrhofer, Maros Ferencik, John T. Nagurney, James E. Udelson, Andreas A. Kammerlander, Jerome L. Fleg, W. Frank Peacock, James L. Januzzi, Wolfgang Koenig, Udo Hoffmann
Summary: The study aimed to quantify differences between high-sensitivity cardiac troponin (hs-cTn) assays and determine whether these differences may result in different management recommendations for patients with suspected acute coronary syndrome (ACS).
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Cian McCarthy, Shuang Li, Tracy Y. Wang, Inbar Raber, Yader Sandoval, Nathaniel R. Smilowitz, Jason H. Wasfy, Ambarish Pandey, James A. de Lemos, Michael C. Kontos, Fred S. Apple, Lori B. Daniels, L. Kristin Newby, Allan S. Jaffe, James L. Januzzi
Summary: This study found that the implementation of high-sensitivity cardiac troponin assays in US hospitals is increasing, but the majority of hospitals still use less sensitive assays. The use of high-sensitivity cardiac troponin assays was associated with increased use of echocardiography for NSTE-ACS patients and reduced use of invasive coronary angiography for low-risk chest pain patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Medical Laboratory Technology
Kwaku Tawiah, Laurel Jackson, Catherine Omosule, Claire Ballman, Bobby Shahideh, Mitchell G. Scott, Gillian Murtagh, Christopher W. Farnsworth
Summary: This study aimed to assess the prognostic and predictive capability of multiple biomarkers in COVID-19 patients. The results showed that baseline hsTnI was the most accurate biomarker for predicting 30-day mortality and the need for intubation. Increasing hsTnI concentrations were associated with poorer survival and higher 30-day mortality risk.
CLINICAL BIOCHEMISTRY
(2022)
Article
Medical Laboratory Technology
Kellisha Harley, Sarah Bissonnette, Rosanna Inzitari, Karen Schulz, Fred S. Apple, Peter A. Kavsak, Ian L. Gunsolus
Summary: The study compared the effects of hemolysis and biotin on cardiac troponin measurements using nine high-sensitivity cardiac troponin assays. Most assays showed interference thresholds equal to or greater than manufacturer's claims, but some assays were susceptible to interference from biotin and hemolysis, resulting in inaccurate measurements of cardiac troponin.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Inbar Raber, Cian P. McCarthy, James L. Januzzi
Summary: High-sensitivity cardiac troponin assays can rapidly identify or exclude acute myocardial injury, providing faster evaluation for acute myocardial infarction, while also opening up possibilities for other cardiovascular risk assessments. The optimal hs-cTn threshold varies depending on the situation, and this review discusses how these assays can be interpreted for different applications.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Medical Laboratory Technology
Ole-Thomas Steiro, Jorund Langorgen, Hilde L. Tjora, Rune O. Bjorneklett, Oyvind Skadberg, Vernon V. S. Bonarjee, Oistein R. Mjelva, Trude Steinsvik, Bertil Lindahl, Torbjorn Omland, Kristin M. Aakre, Kjell Vikenes
Summary: This study aimed to assess the prevalence and association of chronic myocardial injury (CMI) using three different high-sensitivity cardiac troponin (hs-cTn) assays. The results showed that the prevalence of CMI is highly dependent on the assay used, and cTnT and cTnI have similar prognostic accuracy for mortality or cardiovascular events when measured as continuous variables, with cTnT showing higher accuracy in diagnosing CMI compared to cTnI.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Medical Laboratory Technology
Kristin M. Aakre, Amy K. Saenger, Rick Body, Paul Collinson, Ola Hammarsten, Allan S. Jaffe, Pete Kavsak, Torbjorn Omland, Jordi Ordonez-Lianos, Fred S. Apple
Summary: The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides educational documents to promote uniform interpretation and utilization of cardiac biomarkers. The measurement of high-sensitivity cardiac troponin plays a crucial role in evaluating patients with symptoms and/or signs of acute cardiac ischemia.
CLINICAL CHEMISTRY
(2022)
Article
Cardiac & Cardiovascular Systems
Hazem Omran, Marcus A. Deutsch, Elena Groezinger, Armin Zittermann, Andre Renner, Johannes T. Neumann, Dirk Westermann, Paul Myles, Burim Ramosaj, Markus Pauly, Werner Scholtz, Kavous Hakim-Meibodi, Tanja K. Rudolph, Jan Gummert, Volker Rudolph
Summary: This study aimed to determine the optimal cut-off value and timing for high-sensitivity cardiac troponin I (hs-cTnI) in post-operative clinical decision-making. The results showed that hs-cTnI levels measured 12-16 hours after surgery with a cut-off of 8000 ng/L were most strongly correlated with the decision to repeat revascularization. Early hs-cTnI measurements had limited usefulness for clinical decision-making, while measurements at later time-points were more informative.
EUROPEAN HEART JOURNAL
(2022)
Article
Medicine, General & Internal
Kristina Sulskute, Aiste Pilkiene, Emilija Meskene, Dziugile Kersnauskaite, Rokas Serpytis, Zaneta Petrulioniene, Pranas Serpytis
Summary: This study investigates the implementation of diagnostic criteria for UA and NSTEMI in clinical practice, and finds that a significant number of patients with a diagnosis of UA may actually have NSTEMI. It also reveals the presence of myocardial infarction with non-obstructive coronary arteries in some patients.
MEDICINA-LITHUANIA
(2022)
Review
Medical Laboratory Technology
Ellen J. Denessen, Samuel Heuts, Jean H. Daemen, William P. van Doorn, Wim H. Vroemen, Jan-Willem Sels, Patrique Segers, Arnoud W. Van't Hof, Jos G. Maessen, Otto Bekers, Iwan C. Van der Horst, Alma M. Mingels
Summary: Studies have shown that postoperative levels of high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) following CABG exceed most current diagnostic cutoff values. Hs-cTnI was nearly 3 times higher than hs-cTnT, and its levels appeared to be highly dependent on the assay used and surgical strategy. There is a need for assay-specific cutoff values for hs-cTnI and hs-cTnT to accurately identify MI-5 in a timely manner.
CLINICAL CHEMISTRY
(2022)
Article
Cardiac & Cardiovascular Systems
Peter A. Kavsak, Mark K. Hewitt, Shawn E. Mondoux, Joshua O. Cerasuolo, Jinhui Ma, Natasha Clayton, Matthew McQueen, Lauren E. Griffith, Richard Perez, Hsien Seow, Craig Ainsworth, Dennis T. Ko, Andrew Worster
Summary: This study evaluated the diagnostic estimates of three different algorithms using serial hsTnI measurements for ruling out or ruling in acute myocardial infarction or death risk. The COMPASS-MI algorithm showed the highest sensitivity in both ED patient cohorts, while the ESC and COMPASS-MI algorithms exceeded the specificity benchmark. Patient selection for serial hsTnI testing impacted specificity estimates, with no algorithm achieving a sensitivity of >= 99% for 30-day MI or death.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
(2021)
Article
Cardiac & Cardiovascular Systems
Manan Pareek, Kristian H. Kragholm, Anna Meta Dyrvig Kristensen, Muthiah Vaduganathan, Jannik L. Pallisgaard, Christina Byrne, Tor Biering-Sorensen, Christina Ji-Young Lee, Anders Nissen Bonde, Martin Bodtker Mortensen, Michael Maeng, Emil L. Fosbol, Lars Kober, Niels Thue Olsen, Gunnar H. Gislason, Deepak L. Bhatt, Christian Torp-Pedersen
Summary: The study found that individuals suspected of acute coronary syndrome who had consecutively elevated high-sensitivity troponin concentrations had the highest risk of death, while those with consecutively normal hsTnT concentrations had very low mortality rates, regardless of changes between measurements.
EUROPEAN HEART JOURNAL
(2023)
Review
Cardiac & Cardiovascular Systems
Adam Timmis, Denis Kazakiewicz, Nick Townsend, Radu Huculeci, Victor Aboyans, Panos Vardas
Summary: This review provides an overview of global mortality from acute coronary syndromes (ACS) and examines the regional and temporal changes in the epidemiology of ACS over the past 20 years. It shows that mortality from ACS is higher in men than in women, and highest in lower-income global regions. High-income regions have seen progressive reductions in mortality from ACS, while Asia and Latin America have stable levels of mortality. There is a need for more complete epidemiological data to identify countries with the greatest burden of death from ACS and the need for preventive strategies.
NATURE REVIEWS CARDIOLOGY
(2023)
Article
Medical Laboratory Technology
Li Liu, William Consagra, Xueya Cai, Andrew Mathias, Andrew Worster, Jinhui Ma, Philip Rock, Tai Kwong, Peter A. Kavsak
Summary: This study evaluated the use of sex-specific delta thresholds for hs-cTnT assay in diagnosing AMI, finding that these thresholds had high diagnostic accuracy and were robust across different study populations.
CLINICAL CHEMISTRY
(2022)
Article
Medical Laboratory Technology
Amitava Dasgupta, Samir Khalil
Summary: This study investigated the effects of biotin on troponin I assays and found that all three assays were free from biotin interferences up to a biotin concentration of 250 ng/mL. However, a significant positive bias was observed with one of the high sensitivity troponin I assays.
ANNALS OF CLINICAL AND LABORATORY SCIENCE
(2021)
Article
Cardiac & Cardiovascular Systems
Xiaoxi Yao, Zachi I. Attia, Emma M. Behnken, Melissa S. Hart, Shealeigh A. Inselman, Kayla C. Weber, Fan Li, Nikki H. Stricker, John L. Stricker, Paul A. Friedman, Peter A. Noseworthy
Summary: This study aims to explore whether Apple Watch, used as a long-term monitoring device, is effective in the early diagnosis of atrial fibrillation (AF) and the prevention of cognitive function decline in older adults. By using AI-ECG to screen high-risk patients and record electrocardiograms, the effectiveness of Apple Watch will be evaluated. If successful, this approach could have significant implications on how future clinical practice leverages consumer devices for early diagnosis and disease prevention.
AMERICAN HEART JOURNAL
(2024)